Referências: 1. Lohrke J., et al. 25 Years of Contrast-Enhanced MRI: developments Current Challenges and Future Perspectives. Adv Ther.2016.Jan;33:1-28. 2. 2022: Dotarem^® is celebrating 140 million doses administered globally. Disponível em: https://connect.myesr.org/tag/contrast-agent/. Acesso em 31/03/2022. 3. Port M., et al. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals. 2008.21(4): 469–490. 4. Frenzel T., et al. Stability of Gadolinium-Based Magnetic Resonance Imaging Contrast Agents in Human Serum at 37°C. Invest Radiol. 2008.Dec;43(12): 817-288. 5. Runge VM., et al. The developmental history of the gadolinium chelates as intravenous contrast media for magnetic resonance. Invest Radiol. 2011.Dec;46(12):807-16. 6. McKenna Bryant. Guerbet: A Dedication to Medical Imaging. Disponível em: https://www.appliedradiology.com/communities/Pediatric-Imaging/guerbet-a-dedication-to-medical-imaging. Acesso em 31/03/2022. 7. Braun J., et al. Baseline characteristics, diagnostic efficacy, and periexaminational safety of IV gadoteric acid MRI in 148,489 patients. Acta Radiol. 2020.Jul;61(7):910-920. 8. Soyer P., et al. Observational study on the safety profile of gadoterate meglumine in 35,499 patients: The SECURE study. J Magn Reason Imaging. 2017. Apr;45(4):988–997. 9. Chang DH., et al. Safety of gadoterate meglumine in over 1600 children included in the prospective observational SECURE study. Acta Radio. 2019. Nov;60(11):1450–1456. 10. Maravilla K., et al. Comparison of Gadoterate Meglumine and Gadobutrol in the Diagnosis of Primary Brain Tumors: A Double-Blind Randomized Controlled Intraindividual Crossover Study (the REMIND Study). AJNR Am J Neuroradiol. 2017.Sept;38(9):1681-1688.